Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016^[*]

Zusammenfassung

Die vorliegende Leitlinie umfasst ein neues und aktualisiertes Konzept der Behandlung und Prävention von erwachsenen Patienten mit ambulant erworbener Pneumonie und löst die bisherige Leitlinie aus dem Jahre 2009 ab.

Sie wurde entsprechend den Maßgaben zur Methodologie einer S3-Leitlinie erarbeitet und verabschiedet. Hierzu gehören eine systematische Literaturrecherche und -bewertung, die strukturierte Diskussion der aus der Literatur begründbaren Empfehlungen sowie eine Offenlegung und Bewertung möglicher Interessenskonflikte.

Die Leitlinie zeichnet sich aus durch eine Zentrierung auf definierte klinische Situationen, eine aktualisierte Maßgabe der Schweregradbestimmung, Empfehlungen zu einer individualisierten Auswahl der initialen antimikrobiellen Therapie sowie zur primären und sekundären Prävention.

Abstract

The present guideline provides a new and updated concept of treatment and prevention of adult patients with community-acquired pneumonia. It replaces the previous guideline dating from 2009.

The guideline was worked out and agreed on following the standards of methodology of a S3-guideline. This includes a systematic literature search and grading, a structured discussion of recommendations supported by the literature as well as the declaration and assessment of potential conflicts of interests.

The guideline has a focus on specific clinical circumstances, an update on severity assessment, and includes recommendations for an individualized selection of antimicrobial treatment as well as primary and secondary prevention.

• Literatur

• 1 Höffken G, Lorenz J, Kern W et al. [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. Pneumologie 2009; 63: e1-68
• 2 Kopp IB, Lorenz W, Müller W et al. Methodische Empfehlungen zur Leitlinienerstellung. 2004 http://www.uni-duesseldorf.de/AWMF/ll/index. html
• 3 http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk-offline.html
• 4 www.versorgungsleitlinien.de/methodik/reports
• 5 Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490-1494
• 6 Schünemann HJ, Jaeschke R, Cook DJ et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 605-614
• 7 Ewig S. The pneumonia triad. Eur Respir Mon 2014; 63: 13-24
• 8 Viasus D, Garcia-Vidal C, Cruzado JM et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 2899-2906
• 9 Viasus D, Garcia-Vidal C, Castellote J et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine 2011; 90: 110-118
• 10 Di Yacovo S, Garcia-Vidal C, Viasus D et al. Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus. Medicine 2013; 92: 42-50
• 11 Gómez-Junyent J, Garcia-Vidal C, Viasus D et al. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PloS one 2014; 9: e105854
• 12 Belda J, Cavalcanti M, Ferrer M et al. Bronchial colonization and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest 2005; 128: 1571-1579
• 13 Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069
• 14 Ewig S, Klapdor B, Pletz MW et al. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax 2012; 67: 132-138
• 15 Ewig S, Bauer T, Richter K et al. Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J 2013; 41: 917-922
• 16 American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416
• 17 Ewig S, Welte T, Chastre J et al. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010; 10: 279-287
• 18 Chalmers JD, Rother C, Salih W et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58: 330-339
• 19 Klapdor B, Ewig S, Pletz MW et al. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J 2012; 39: 1156-1161
• 20 Schaberg T, Bauer T, Dalhoff K et al. Management der neuen Influenza A/H1N1-Virus-Pandemie im Krankenhaus: Eine Stellungnahme der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie 2009; 63: 417-425
• 21 Porten K, Rissland J, Tigges A et al. A super-spreading ewe infects hundreds with Q fever at a farmersʼ market in Germany. BMC Infect Dis 2006; 6: 147
• 22 von Baum H, Härter G, Essig A et al. Preliminary report: outbreak of Legionnaires disease in the cities of Ulm and Neu-Ulm in Germany, December 2009–January 2010. Euro Surveill 2010; 15: 19472
• 23 Covinsky KES, Palmer RM, Fortinsky RH et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc 2003; 51: 451-458
• 24 Covinsky KE, Pierluissi E, Johnston CB. Hospitalization-associated disability: “She was probably able to ambulate, but I'm not sure”. JAMA 2011; 306: 1782-1793
• 25 Leff B, Burton L, Mader SL et al. Hospital at home: feasibility and outcomes of a program to provide hospital-level care at home for acutely ill older patients. Ann Intern Med 2005; 143: 798-808
• 26 Leff B, Burton L, Mader S et al. Satisfaction with hospital at home care. J Am Geriatr Soc 2006; 54: 1355-1363
• 27 Leff B, Burton L, Mader S et al. Comparison of functional outcomes associated with hospital at home care and traditional acute hospital care. J Am Geriatr Soc 2009; 57: 273-278
• 28 Diehr P, Wood RW, Bushyhead J et al. Prediction of pneumonia in outpatients with acute cough – a statistical approach. J Chronic Dis 1984; 37: 215-225
• 29 Gennis P, Gallagher J, Falvo C et al. Clinical criteria for the detection of pneumonia in adults: guidelines for ordering chest roentgenograms in the emergency department. J Emerg Med 1989; 7: 263-268
• 30 Heckerling PS, Tape TG, Wigton RS et al. Clinical prediction rule for pulmonary infiltrates. Ann Intern Med 1990; 113: 664-670
• 31 Melbye H, Straume B, Aasebø U et al. Diagnosis of pneumonia in adults in general practice. Relative importance of typical symptoms and abnormal chest signs evaluated against a radiographic reference standard. Scand J Prim Health Care 1992; 10: 226-233
• 32 Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278: 1440-1445
• 33 Wipf JE, Lipsky BA, Hirschmann JV et al. Diagnosing pneumonia by physical examination: relevant or relic?. Arch Intern Med 1999; 159: 1082-1087
• 34 van Vugt SF, Verheij TJ, de Jong PA et al. Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography. Eur Respir J 2013; 42: 1076-1082
• 35 Lieberman D, Shvartzman P, Korsonsky I et al. Diagnosis of ambulatory community-acquired pneumonia. Comparison of clinical assessment versus chest X-ray. Scand J Prim Health Care 2003; 21: 57-60
• 36 OʼBrien Sr WT, Rohweder DA, Lattin Jr GE et al. Clinical indicators of radiographic findings in patients with suspected community-acquired pneumonia: who needs a chest x-ray. J Am Coll Radiol 2006; 3: 703-706
• 37 Metlay JP, Schulz R, Li YH et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453-1459
• 38 Bewick T, Greenwood S, Lim WS. The impact of an early chest radiograph on outcome in patients hospitalised with community-acquired pneumonia. Clin Med 2010; 10: 563-567
• 39 Speets AM, Hoes AW, van der Graaf Y et al. Chest radiography and pneumonia in primary care: diagnostic yield and consequences for patient management. Eur Respir J 2006; 28: 933-938
• 40 Falguera M, Martín M, Ruiz-González A et al. Community-acquired pneumonia as the initial manifestation of serious underlying diseases. Am J Med 2005; 118: 378-383
• 41 Hagaman JT, Rouan GW, Shipley RT et al. Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. Am J Med Sci 2009; 337: 236-240
• 42 Melbye H, Dale K. Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia. Acta Radiol 1992; 33: 79-81
• 43 Young M, Marrie TJ. Interobserver variability in the interpretation of chest roentgenograms of patients with possible pneumonia. Arch Intern Med 1994; 154: 2729-2732
• 44 Moncada DC, Rueda ZV, Macías A et al. Reading and interpretation of chest X-ray in adults with community-acquired pneumonia. Braz J Infect Dis 2011; 15: 540-546
• 45 Basi SK, Marrie TJ, Huang JQ et al. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2004; 117: 305-311
• 46 Reissig A, Copetti R, Mathis G et al. Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia: a prospective, multicenter, diagnostic accuracy study. Chest 2012; 142: 965-972
• 47 van der Meer V, Neven AK, van den Broek PJ et al. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005; 331: 26
• 48 Holm A, Pedersen SS, Nexoe J et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract 2007; 57: 555-560
• 49 Engel MF, Paling FP, Hoepelman AIM et al. Evaluating the evidence for the implementation of C-reactive protein measurement in adult patients with suspected lower respiratory tract infection in primary care: a systematic review. Fam Pract 2012; 29: 383-393
• 50 Müller F, Christ-Crain M, Bregenzer T et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010; 138: 121-129
• 51 Almirall J, Bolíbar I, Toran P et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335-1342
• 52 Huang Y, Chen R, Wu T et al. Association between point-of-care CRP testing and antibiotic prescribing in respiratory tract infections: a systematic review and meta-analysis of primary care studies. Br J Gen Pract 2013; 63: e787-794
• 53 Aabenhus R, Jensen JU, Jørgensen KJ et al. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. Cochrane Database Syst Rev 2014; 11: CD010130
• 54 Burkhardt O, Ewig S, Haagen U et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010; 36: 601-607
• 55 Schuetz P, Müller B, Christ-Crain M et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9: CD007498
• 56 Bauer TT, Ewig S, Marre R et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260: 93-101
• 57 Loke YK, Kwok CS, Niruban A et al. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010; 65: 884-890
• 58 Chalmers JD, Singanayagam A, Akram AR et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010; 65: 878-883
• 59 Chalmers JD, Mandal P, Singanayagam A et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011; 37: 1409-1420
• 60 Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J 2014; 43: 842-851
• 61 Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382
• 62 Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250
• 63 Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011; 37: 214-223
• 64 Kolditz M, Ewig S, Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013; 41: 974-984
• 65 Strauß R, Ewig S, Richter K et al. The prognostic significance of respiratory rate in patients with pneumonia: a retrospective analysis of data from 705,928 hospitalized patients in Germany from 2010-2012. Dtsch Arztebl Int 2014; 111: 503-508
• 66 Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM 2011; 104: 871-879
• 67 McNally M, Curtain J, O'Brien KK et al. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract 2010; 60: e423-433
• 68 Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2011; 37: 858-864
• 69 Bont J, Hak E, Hoes AW et al. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Arch Intern Med 2008; 168: 1465-1468
• 70 Torres OH, Muñoz J, Ruiz D et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. J Am Geriatr Soc 2004; 52: 1603-1609
• 71 Naito T, Suda T, Yasuda K et al. A validation and potential modification of the pneumonia severity index in elderly patients with community-acquired pneumonia. J Am Geriatr Soc 2006; 54: 1212-1219
• 72 Murcia J, Llorens P, Sánchez-Payá J et al. Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population. J Infect 2010; 61: 458-464
• 73 Corrales-Medina VF, Musher DM, Wells GA et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125: 773-781
• 74 Kothe H, Bauer T, Marre R et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32: 139-146
• 75 Akram AR, Singanayagam A, Choudhury G et al. Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia. Chest 2010; 138: 825-832
• 76 Yende S, van der Poll T, Lee M et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax 2010; 65: 870-877
• 77 Dwyer R, Hedlund J, Darenberg J et al. Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia. Scand J Infect Dis 2011; 43: 448-455
• 78 Dwyer R, Hedlund J, Henriques-Normark B et al. Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia. BMJ Open Respir Res 2014; 1: e000038
• 79 Kolditz M, Ewig S, Schütte H et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med 2015; 278: 193-202
• 80 Dremsizov T, Clermont G, Kellum JA et al. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course. Chest 2006; 129: 968-978
• 81 Aliberti S, Amir A, Peyrani P et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008; 134: 955-962
• 82 Schaaf B, Kruse J, Rupp J et al. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J 2007; 30: 517-524
• 83 Aliberti S, Brambilla AM, Chalmers JD et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res 2014; 15: 1-10
• 84 El-Solh AA, Alhajhusain A, Abou Jaoude P et al. Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. Chest 2010; 138: 1371-1376
• 85 Bewick T, Greenwood S, Lim WS. What is the role of pulse oximetry in the assessment of patients with community-acquired pneumonia in primary care. Prim Care Respir J 2010; 19: 378-382
• 86 Carr GE, Yuen TC, McConville JF et al. Early cardiac arrest in patients hospitalized with pneumonia: a report from the American Heart Associationʼs Get With The Guidelines-Resuscitation Program. Chest 2012; 141: 1528-1536
• 87 Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J 2010; 36: 826-833
• 88 Ewig S, Ruiz M, Mensa J et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998; 158: 1102-1108
• 89 Angus DC, Marrie TJ, Obrosky DS et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717-723
• 90 Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596
• 91 Puskarich MA, Trzeciak S, Shapiro NI et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011; 39: 2066-2071
• 92 Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637
• 93 Reinhart K, Brunkhorst FM, Bone HG et al. [Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)]. Anaesthesist 2010; 59: 347-370
• 94 Rodriguez A, Lisboa T, Blot S et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009; 35: 430-438
• 95 Gattarello S, Borgatta B, Solé-Violán J et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest 2014; 146: 22-31
• 96 Sirvent JM, Carmen de la Torre M, Lorencio C et al. Predictive factors of mortality in severe community-acquired pneumonia: a model with data on the first 24h of ICU admission. Med Intensiva 2013; 37: 308-315
• 97 Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: 27-72
• 98 Chalmers JD, Taylor JK, Mandal P et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011; 53: 503-511
• 99 Charles PGP, Wolfe R, Whitby M et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375-384
• 100 España PP, Capelastegui A, Gorordo I et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174: 1249-1256
• 101 Yandiola PP, Capelastegui A, Quintana J et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 2009; 135: 1572-1579
• 102 Buising KL, Thursky KA, Black JF et al. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas 2007; 19: 418-426
• 103 Renaud B, Labarère J, Coma E et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care 2009; 13: R54
• 104 Kolditz M, Ewig S, Klapdor B et al. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax 2015; 70: 551-558
• 105 Marti C, Garin N, Grosgurin O et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012; 16: R141
• 106 Brown SM, Jones BE, Jephson AR et al. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009; 37: 3010-3016
• 107 Liapikou A, Ferrer M, Polverino E et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009; 48: 377-385
• 108 Phua J, See KC, Chan YH et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009; 64: 598-603
• 109 Fukuyama H, Ishida T, Tachibana H et al. Validation of scoring systems for predicting severe community-acquired pneumonia. Intern Med 2011; 50: 1917-1922
• 110 Lim HF, Phua J, Mukhopadhyay A et al. IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. Eur Respir J 2014; 43: 852-862
• 111 Lepper PM, Ott S, Nüesch E et al. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 2012; 344: e3397
• 112 Krüger S, Ewig S, Giersdorf S et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182: 1426-1434
• 113 Krüger S, Ewig S, Kunde J et al. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 2010; 65: 208-214
• 114 Albrich WC, Dusemund F, Rüegger K et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011; 11: 1-12
• 115 Kolditz M, Höffken G, Martus P et al. Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis 2012; 12: 90
• 116 Albrich WC, Rüegger K, Dusemund F et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J 2013; 42: 1064-1075
• 117 Jones AE, Shapiro NI, Trzeciak S et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010; 303: 739-746
• 118 Puskarich MA, Trzeciak S, Shapiro NI et al. Whole blood lactate kinetics in patients undergoing quantitative resuscitation for severe sepsis and septic shock. Chest 2013; 143: 1548-1553
• 119 Carratalà J, Fernández-Sabé N, Ortega L et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 2005; 142: 165-172
• 120 Choudhury G, Chalmers JD, Mandal P et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J 2011; 38: 643-648
• 121 Chen JH, Chang SS, Liu JJ et al. Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects. Thorax 2010; 65: 971-977
• 122 Zeymer U, Hambrecht R, Theres H et al. Treatment of ST-segment elevation acute myocardial infarction in hospitals with and without cardiac catheterization laboratory. Dtsch Med Wochenschr 2013; 138: 1935-1940
• 123 Bauer TT, Welte T, Strauss R et al. Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support. Lung 2013; 191: 417-724
• 124 Renaud B, Santin A, Coma E et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37: 2867-2874
• 125 Ferrer R, Martin-Loeches I, Phillips G et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749-1755
• 126 Restrepo MI, Mortensen EM, Rello J et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137: 552-557
• 127 Blot SI, Rodriguez A, Solé-Violán J et al. Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 2007; 35: 2509-2514
• 128 Chamberlain DJ, Willis EM, Bersten AB. The severe sepsis bundles as processes of care: a meta-analysis. Aust Crit Care 2011; 24: 229-243
• 129 Lee SJ, Ramar K, Park JG et al. Increased fluid administration in the first three hours of sepsis resuscitation is associated with reduced mortality: a retrospective cohort study. Chest 2014; 146: 908-915
• 130 Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin. S3-Leitlinie Intravasale Volumentherapie beim Erwachsenen. 2014 http://www.awmf.org AWMF-Registernummer 001/020
• 131 Menéndez R, Torres A, Reyes S et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012; 39: 156-162
• 132 Hortmann M, Heppner HJ, Popp S et al. Reduction of mortality in community-acquired pneumonia after implementing standardized care bundles in the emergency department. Eur J Emerg Med 2014; 21: 429-435
• 133 Miller RR, Dong L, Nelson NC et al. Multicenter implementation of a severe sepsis and septic shock treatment bundle. Am J Respir Crit Care Med 2013; 188: 77-82
• 134 Levy MM, Dellinger RP, Townsend SR et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010; 38: 367-374
• 135 Nguyen HB, Corbett SW, Steele R et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med 2007; 35: 1105-1112
• 136 Ferrer R, Artigas A, Levy MM et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008; 299: 2294-2303
• 137 Kortgen A, Niederprüm P, Bauer M. Implementation of an evidence-based “standard operating procedure” and outcome in septic shock. Crit Care Med 2006; 34: 943-949
• 138 Mortensen EM, Coley CM, Singer DE et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162: 1059-1064
• 139 Ewig S, Torres A. Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. Eur Respir J 2011; 38: 253-260
• 140 Krüger S, Frechen D. Cardiovascular Complications in Community-acquired Pneumonia. Clinical Pulmonary Medicine 2015; 22: 62-67
• 141 Brodhun B, Buchholz U. Legionärskrankheit in Deutschland (2001–2013). Epidemiologisches Bulletin 2015; 13: 95-107
• 142 Schneeberger PM, Wintenberger C, van der Hoek W et al. Q fever in the Netherlands - 2007-2010: what we learned from the largest outbreak ever. Med Mal Infect 2014; 44: 339-353
• 143 Capelastegui A, España PP, Bilbao A et al. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 2012; 12: 134
• 144 Cillóniz C, Ewig S, Polverino E et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 2012; 40: 931-938
• 145 Chaisuksant S, Koonsuwan A, Sawanyawisuth K. Appropriateness of obtaining blood cultures in patients with community acquired pneumonia. Southeast Asian J Trop Med Public Health 2013; 44: 289-294
• 146 Torres A, Cillóniz C, Ferrer M et al. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J 2015; 45: 1353-1363
• 147 Johansson N, Kalin M, Tiveljung-Lindell A et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50: 202-209
• 148 Said MA, Johnson HL, Nonyane BA et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PloS one 2013; 8: e60273
• 149 Capelastegui A, Zalacain R, Bilbao A et al. Pneumococcal pneumonia: differences according to blood culture results. BMC Pulm Med 2014; 14: 128
• 150 Ingarfield SL, Celenza A, Jacobs IG et al. The bacteriology of pneumonia diagnosed in Western Australian emergency departments. Epidemiol Infect 2007; 135: 1376-1383
• 151 von Baum H, Welte T, Marre R et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010; 35: 598-605
• 152 Shimada T, Noguchi Y, Jackson JL et al. Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest 2009; 136: 1576-1585
• 153 Roed T, Schønheyder HC, Nielsen H. Predictors of positive or negative legionella urinary antigen test in community-acquired pneumonia. Infect Dis 2015; 47: 484-490
• 154 Ewig S, Schlochtermeier M, Göke N et al. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002; 121: 1486-1492
• 155 Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987; 25: 758-762
• 156 Rosón B, Carratalà J, Verdaguer R et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000; 31: 869-874
• 157 Anevlavis S, Petroglou N, Tzavaras A et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009; 59: 83-89
• 158 Fukuyama H, Yamashiro S, Kinjo K et al. Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia: a prospective observational study. BMC Infect Dis 2014; 18: 534
• 159 Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975; 50: 339-344
• 160 Sommer F, Elias J, Griese M et al. Mikrobiologisch-Infektiologische Qualitätsstandards (MiQ) 7: Infektionen der tiefen Atemwege, Teil I. Urban & Fischer in Elsevier Verlag; 2010
• 161 Noone P, Rogers BT. Pneumonia caused by coliforms and Pseudomonas aeruginosa. J Clin Pathol 1976; 29: 652-656
• 162 Horita N, Miyazawa N, Kojima R et al. Sensitivity and specificity of the Streptococcus pneumoniae urinary antigen test for unconcentrated urine from adult patients with pneumonia: a meta-analysis. Respirology 2013; 18: 1177-1183
• 163 Sinclair A, Xie X, Teltscher M et al. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 2013; 51: 2303-2310
• 164 Andreo F, Ruiz-Manzano J, Prat C et al. Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients. Respir Med 2010; 104: 397-403
• 165 Hamer DH, Egas J, Estrella B et al. Assessment of the Binax NOW Streptococcus pneumoniae urinary antigen test in children with nasopharyngeal pneumococcal carriage. Clin Infect Dis 2002; 34: 1025-1028
• 166 Edin A, Granholm S, Koskiniemi S et al. Development and laboratory evaluation of a real-time PCR assay for detecting viruses and bacteria of relevance for community-acquired pneumonia. J Mol Diagn 2015; 17: 315-324
• 167 Huijskens EG, van Erkel AJ, Palmen FM et al. Viral and bacterial aetiology of community-acquired pneumonia in adults. Influenza Other Respir Viruses 2013; 7: 567-573
• 168 Das D, Le Floch H, Houhou N et al. Viruses detected by systematic multiplex polymerase chain reaction in adults with suspected community-acquired pneumonia attending emergency departments in France. Clin Microbiol Infect 2015; 21: e1-8
• 169 Costa E, Rodríguez-Domínguez M, Clari MÁ et al. Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens. Diagn Microbiol Infect Dis 2015; 82: 40-43
• 170 Choi SH, Hong SB, Ko GB et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012; 186: 325-332
• 171 Thurman KA, Warner AK, Cowart KC et al. Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay. Diagn Microbiol Infect Dis 2011; 70: 1-9
• 172 Schack M, Sachse S, Rödel J et al. Coxiella burnetii (Q fever) as a cause of community-acquired pneumonia during the warm season in Germany. Epidemiol Infect 2014; 142: 1905-1910
• 173 Corman VM, Ölschläger S, Wendtner CM et al. Performance and clinical validation of the RealStar MERS-CoV Kit for detection of Middle East respiratory syndrome coronavirus RNA. J Clin Virol 2014; 60: 168-171
• 174 Gago S, Buitrago MJ, Clemons KV et al. Development and validation of a quantitative real-time PCR assay for the early diagnosis of coccidioidomycosis. Diagn Microbiol Infect Dis 2014; 79: 214-221
• 175 Antinori S. Histoplasma capsulatum: more widespread than previously thought. Am J Trop Med Hyg 2014; 90: 982-983
• 176 Scheel CM, Zhou Y, Theodoro RC et al. Development of a loop-mediated isothermal amplification method for detection of Histoplasma capsulatum DNA in clinical samples. J Clin Microbiol 2014; 52: 483-488
• 177 Chen SC, Meyer W, Sorrell TC. Cryptococcus gattii infections. Clin Microbiol Rev 2014; 27: 980-1024
• 178 Beckmann C, Hirsch HH. Diagnostic performance of near-patient testing for influenza. J Clin Virol 2015; 67: 43-46
• 179 Chartrand C, Leeflang MM, Minion J et al. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012; 156: 500-511
• 180 Hazelton B, Nedeljkovic G, Ratnamohan VM et al. Evaluation of the Sofia Influenza A + B fluorescent immunoassay for the rapid diagnosis of influenza A and B. J Med Virol 2015; 87: 35-38
• 181 Tuttle R, Weick A, Schwarz WS et al. Evaluation of novel second-generation RSV and influenza rapid tests at the point of care. Diagn Microbiol Infect Dis 2015; 81: 171-176
• 182 Binnicker MJ, Espy MJ, Irish CL et al. Direct Detection of Influenza A and B Viruses in Less Than 20 Minutes Using a Commercially Available Rapid PCR Assay. J Clin Microbiol 2015; 53: 2353-2354
• 183 Nie S, Roth RB, Stiles J et al. Evaluation of Alere i Influenza A&B for rapid detection of influenza viruses A and B. J Clin Microbiol 2014; 52: 3339-3344
• 184 Salez N, Nougairede A, Ninove L et al. Prospective and retrospective evaluation of the Cepheid Xpert^® Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus. Diagn Microbiol Infect Dis 2015; 81: 256-258
• 185 Ewig S, Torres A, Angeles Marcos M et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002; 20: 1254-1262
• 186 Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-1457
• 187 Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am J Med 1990; 89: 713-721
• 188 Halm EA, Fine MJ, Kapoor WN et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-1284
• 189 Ruiz-González A, Falguera M, Porcel JM et al. C-reactive protein for discriminating treatment failure from slow responding pneumonia. Eur J Intern Med 2010; 21: 548-552
• 190 Coelho L, Póvoa P, Almeida E et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11: R92
• 191 Coelho LM, Salluh JI, Soares M et al. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care 2012; 16: R53
• 192 Little BP, Gilman MD, Humphrey KL et al. Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography. AJR Am J Roentgenol 2014; 202: 54-59
• 193 Mortensen EM, Copeland LA, Pugh MJ et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia. Am J Med 2010; 123: 66-71
• 194 Syrjälä H, Broas M, Suramo I et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27: 358-363
• 195 von Baum H, Ewig S, Marre R et al. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 2008; 46: 1356-1364
• 196 Wellinghausen N, Straube E, Freidank H et al. Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia. Int J Med Microbiol 2006; 296: 485-491
• 197 Dumke R, Schnee C, Pletz MW et al. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerg Infect Dis 2015; 21: 426-434
• 198 von Baum H, Welte T, Marre R et al. Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis 2009; 9: 62
• 199 Imöhl M, van der Linden M. [Invasive pneumococcal disease in Germany in the era of pneumococcal conjugate vaccination]. Dtsch Med Wochenschr 2015; 139: 1346-1351
• 200 Pletz MW, McGee L, Burkhardt O et al. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 58-60
• 201 Ben-Ami R, Rodríguez-Baño J, Arslan H et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-690
• 202 Creutz P, Kothe H, Braun M et al. Failure of Ambulatory Treatment in CAP Patients Leading to Subsequent Hospitalization and its Association to Risk Factors - Prospective Cohort Study. J Pulmon Resp Med 2013; 3: 1-7
• 203 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79
• 204 Lode H. Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. Int J Antimicrob Agents 2001; 18: 199-209
• 205 Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 1441-1446
• 206 Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330: 456
• 207 Tessmer A, Welte T, Martus P et al. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009; 63: 1025-1033
• 208 Garin N, Genné D, Carballo S et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014; 174: 1894-1901
• 209 Postma DF, van Werkhoven CH, van Elden LJ et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372: 1312-1323
• 210 Guo D, Cai Y, Chai D et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie 2010; 65: 631-640
• 211 von Baum H, Schweiger B, Welte T et al. How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia. Eur Respir J 2011; 37: 1151-1157
• 212 Louie JK, Yang S, Acosta M et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55: 1198-1204
• 213 Rodríguez A, Díaz E, Martín-Loeches I et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011; 66: 1140-1149
• 214 Jefferson T, Jones MA, Doshi P et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; 1: CD008965
• 215 Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2: 395-404
• 216 Viasus D, Paño-Pardo JR, Pachón J et al. Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect 2011; 17: 738-746
• 217 Klapdor B, Ewig S, Schaberg T et al. Presentation, etiology and outcome of pneumonia in younger nursing home residents. J Infect 2012; 65: 32-38
• 218 Kett DH, Cano E, Quartin AA et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011; 11: 181-189
• 219 Attridge RT, Frei CR, Restrepo MI et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 2011; 38: 878-887
• 220 Madaras-Kelly KJ, Remington RE, Sloan KL et al. Guideline-based antibiotics and mortality in healthcare-associated pneumonia. J Gen Intern Med 2012; 27: 845-852
• 221 Biehl LM, Schmidt-Hieber M, Liss B et al. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. Crit Rev Microbiol 2014; [Epub ahead of print: 2014 Feb 4]
• 222 Rodríguez-Baño J, Navarro MD, Retamar P et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2015; 54: 167-174
• 223 Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 35: 1888-1895
• 224 Chamot E, Boffi E, Rohner P et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47: 2756-2764
• 225 Dalhoff K, Abele-Horn M, Andreas S et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S-3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy. Pneumologie 2012; 66: 707-765
• 226 Maschmeyer G, Carratalà J, Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 2015; 26: 21-33
• 227 Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40: 32-40
• 228 Morel J, Casoetto J, Jospé R et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Critical care 2010; 14: R225
• 229 Cremers AJ, Sprong T, Schouten JA et al. Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia. J Antimicrob Chemother 2014; 169: 2258-2264
• 230 de With K, Allerberger F, Amann S et al. S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. 2013 AWMF-Registernummer 092/001
• 231 van der Eerden MM, Vlaspolder F, de Graaff CS et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672-678
• 232 Cillóniz C, Ewig S, Ferrer M et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Critical care 2011; 15: R209
• 233 Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 2005; 55: 10-21
• 234 Baddour LM, Yu VL, Klugman KP et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-444
• 235 Blasi F, Garau J, Medina J et al. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Respir Res 2013; 14: 1-10
• 236 Ostrowsky B, Sharma S, DeFino M et al. Antimicrobial stewardship and automated pharmacy technology improve antibiotic appropriateness for community-acquired pneumonia. Infect Control Hosp Epidemiol 2013; 34: 566-572
• 237 Schouten JA, Hulscher ME, Trap-Liefers J et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. Clin Infect Dis 2007; 44: 931-941
• 238 Avdic E, Cushinotto LA, Hughes AH et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis 2012; 54: 1581-1587
• 239 Li JZ, Winston LG, Moore DH et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120: 783-790
• 240 Dimopoulos G, Matthaiou DK, Karageorgopoulos DE et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008; 68: 1841-1854
• 241 Pinzone MR, Cacopardo B, Abbo L et al. Duration of antimicrobial therapy in community acquired pneumonia: less is more. ScientificWorldJournal 2014; 2014
• 242 el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332: 1355
• 243 Rizzato G, Montemurro L, Fraioli P et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995; 8: 398-402
• 244 OʼDoherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17: 828-833
• 245 Sopena N, Martínez-Vázquez C, Rodríguez-Suárez JR et al. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J Chemother 2004; 16: 102-103
• 246 Paris R, Confalonieri M, Dal Negro R et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 2008; 20: 77-86
• 247 Dunbar LM, Khashab MM, Kahn JB et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20: 555-563
• 248 DʼIgnazio J, Camere MA, Lewis DE et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother 2005; 49: 4035-4041
• 249 Choudhury G, Mandal P, Singanayagam A et al. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia – a propensity-adjusted analysis. Clin Microbiol Infect 2011; 17: 1852-1858
• 250 Athanassa Z, Makris G, Dimopoulos G et al. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 2008; 68: 2469-2481
• 251 Oosterheert JJ, Bonten MJ, Schneider MM et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006; 333: 1193
• 252 Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011; 15: R267
• 253 Sabrià M, Pedro-Botet ML, Gómez J et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128: 1401-1405
• 254 Griffin AT, Peyrani P, Wiemken T et al. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. Int J Tuberc Lung Dis 2010; 14: 495-499
• 255 Viasus D, Di Yacovo S, Garcia-Vidal C et al. Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. Medicine 2013; 92: 51-60
• 256 Nagel JL, Rarus RE, Crowley AW et al. Retrospective analysis of azithromycin versus fluoroquinolones for the treatment of legionella pneumonia. P T 2014; 39: 203-205
• 257 Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752-760
• 258 Yu VL, Greenberg RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 2135-2139
• 259 Omidvari K, de Boisblanc BP, Karam G et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92: 1032-1039
• 260 Rhew DC, Tu GS, Ofman J et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722-727
• 261 Carratalà J, Garcia-Vidal C, Ortega L et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012; 172: 922-928
• 262 Engel MF, Bruns AH, Hulscher ME et al. A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study. Eur J Clin Microbiol Infect Dis 2014; 33: 1897-1908
• 263 Verhaegen J, Verbist L. In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 1998; 41: 381-385
• 264 Peric M, Browne FA, Jacobs MR et al. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin Ther 2003; 25: 169-177
• 265 Morrissey I, Leakey A. Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007–08). J Antimicrob Chemother 2012; 67: 1408-1412
• 266 Balfour JA, Balfour JA, Benfield P. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections. PharmacoEconomics 1996; 10: 164-178
• 267 Perry CM, Brogden RN. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1996; 52: 125-158
• 268 Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111: 367-374
• 269 Long W, Deng X, Zhang Y et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011; 16: 819-824
• 270 Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93
• 271 Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patientsʼ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463-474
• 272 Ram FS, Picot J, Lightowler J et al. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; 3: CD004104
• 273 Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013; 5: CD005351
• 274 Schönhofer B, Kuhlen R, Neumann P et al. Nichtinvasive Beatmung als Therapie der akuten respiratorischen Insuffizienz. Pneumologie 2008; 62: 449-479
• 275 Confalonieri M, Potena A, Carbone G et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999; 160: 1585-1591
• 276 Ferrer M, Esquinas A, Leon M et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003; 168: 1438-1444
• 277 Carrillo A, Gonzalez-Diaz G, Ferrer M et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med 2012; 38: 458-466
• 278 Frat JP, Thille AW, Mercat A et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372: 2185-2196
• 279 Ambrosino N, Foglio K, Rubini F et al. Non-invasive mechanical ventilation in acute respiratory failure due to chronic obstructive pulmonary disease: correlates for success. Thorax 1995; 50: 755-757
• 280 Antonelli M, Conti G, Moro ML et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med 2001; 27: 1718-1728
• 281 Jolliet P, Abajo B, Pasquina P et al. Non-invasive pressure support ventilation in severe community-acquired pneumonia. Intensive Care Med 2001; 27: 812-821
• 282 Domenighetti G, Gayer R, Gentilini R. Noninvasive pressure support ventilation in non-COPD patients with acute cardiogenic pulmonary edema and severe community-acquired pneumonia: acute effects and outcome. Intensive Care Med 2002; 28: 1226-1232
• 283 Murad A, Li PZ, Dial S et al. The role of noninvasive positive pressure ventilation in community-acquired pneumonia. J Crit Care 2015; 30: 49-54
• 284 Nicolini A, Ferraioli G, Ferrari-Bravo M et al. Early non-invasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia. Clin Respir J 2016; 10: 98-103
• 285 Demoule A, Girou E, Richard JC et al. Benefits and risks of success or failure of noninvasive ventilation. Intensive Care Med 2006; 32: 1756-1765
• 286 Rana S, Jenad H, Gay PC et al. Failure of non-invasive ventilation in patients with acute lung injury: observational cohort study. Crit Care 2006; 10: R79
• 287 Cosentini R, Brambilla AM, Aliberti S et al. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. Chest 2010; 138: 114-120
• 288 Brambilla AM, Aliberti S, Prina E et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Med 2014; 40: 942-949
• 289 Putensen C, Theuerkauf N, Zinserling J et al. Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Ann Intern Med 2009; 151: 566-576
• 290 Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377
• 291 ProCESS Investigators. Yealy DM, Kellum JA et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370: 1683-1693
• 292 ARISE Investigators, ANZICS Clinical Trials Group. Peake SL et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014; 371: 1496-1506
• 293 Mundy LM, Leet TL, Darst K et al. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124: 883-889
• 294 Cangemi R, Calvieri C, Falcone M et al. Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. Am J Cardiol 2015; 116: 647-651
• 295 Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. Int J Infect Dis 2013; 17: e1125-1129
• 296 Oz F, Gul S, Kaya MG et al. Does ASS use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. Coron Artery Dis 2013; 24: 231-237
• 297 Falcone M, Russo A, Cangemi R et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with ASS. J Am Heart Assoc 2015; 4: e001595
• 298 Cangemi R, Casciaro M, Rossi E et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014; 64: 1917-1925
• 299 Dellinger RP, Levy MM, Rhodes A et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med 2013; 39: 165-228
• 300 Global Strategy for Asthma Management and Prevention: GINA executive summary. 2015 http://www.ginasthma.org/local/uploads/files/GINA_Report_2015.pdf
• 301 Walters JA, Tan DJ, White CJ et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 12: CD006897
• 302 Salluh JI, Póvoa P, Soares M et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008; 12: R76
• 303 Siempos II, Vardakas KZ, Kopterides P et al. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008; 62: 661-668
• 304 Lamontagne F, Briel M, Guyatt GH et al. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care 2010; 25: 420-435
• 305 Chen Y, Li K, Pu H et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2011; 3: CD007720
• 306 Nie W, Zhang Y, Cheng J et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PloS one 2012; 7: e47926
• 307 Shafiq M, Mansoor MS, Khan AA et al. Adjuvant steroid therapy in community-acquired pneumonia: a systematic review and meta-analysis. J Hosp Med 2013; 8: 68-75
• 308 Blum CA, Nigro N, Briel M et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015; 385: 1511-1518
• 309 Torres A, Sibila O, Ferrer M et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313: 677-686
• 310 ADRENAL Studie: ClinicalTrials.gov NCT01448109; ESCAPe Studie: ClinicalTrials.gov NCT01283009.
• 311 Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS et al. Effect of Corticosteroid Therapy on Influenza-Related Mortality: A Systematic Review and Meta-analysis. J Infect Dis 2015; 212: 183-194
• 312 World Health Organization. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1)2009 and other Influenza Viruses_2009_WHO. 2010 http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf?ua=1
• 313 Myles P, Nguyen-Van-Tam JS, Semple MG et al. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J 2013; 41: 824-831
• 314 Menéndez R, Torres A, Rodríguez de Castro F et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-1790
• 315 Menéndez R, Torres A, Zalacaín R et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965
• 316 Arancibia F, Ewig S, Martinez JA et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 154-160
• 317 Rosón B, Carratalà J, Fernández-Sabé N et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164: 502-508
• 318 Genné D, Sommer R, Kaiser L et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 159-166
• 319 Hoogewerf M, Oosterheert JJ, Hak E et al. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect 2006; 12: 1097-1104
• 320 Kaye KS, Harris AD, McDonald JR et al. Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistance. Infect Control Hosp Epidemiol 2008; 29: 137-142
• 321 Ye X, Sikirica V, Schein JR et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008; 30: 358-371
• 322 Menéndez R, Cavalcanti M, Reyes S et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63: 447-452
• 323 Hess G, Hill JW, Raut MK et al. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis. Adv Ther 2010; 27: 743-755
• 324 Ott SR, Hauptmeier BM, Ernen C et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J 2012; 39: 611-618
• 325 Marrie TJ. Normal resolution of community-acquired pneumonia. Semin Respir Infect 1992; 7: 256-270
• 326 Mittl RL, Schwab RJ, Duchin JS et al. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994; 149: 630-635
• 327 El Solh AA, Aquilina AT, Gunen H et al. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004; 52: 224-229
• 328 Metlay JP, Fine MJ, Schulz R et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997; 12: 423-430
• 329 El Moussaoui R, Opmeer BC, de Borgie CA et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest 2006; 130: 1165-1172
• 330 Boussekey N, Leroy O, Alfandari S et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32: 469-472
• 331 Martin-Loeches I, Valles X, Menendez R et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respir Res 2014; 15: 75
• 332 Zhydkov A, Christ-Crain M, Thomann R et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med 2014; 53: 559-566
• 333 Woodhead M, Welch CA, Harrison DA et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006; 10: S1
• 334 Pereira Gomes JC, Pedreira WL, Araújo EM et al. Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy. Chest 2000; 118: 1739-1746
• 335 Pedro-Botet ML, Sabrià M, Sopena N et al. Legionnaires disease and HIV infection. Chest 2003; 124: 543-547
• 336 Musher DM, Rueda AM, Kaka AS et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45: 158-165
• 337 Ramirez J, Aliberti S, Mirsaeidi M et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47: 182-187
• 338 Menéndez R, Perpiñá M, Torres A. Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 2003; 18: 103-111
• 339 Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med 1998; 105: 319-330
• 340 Kuru T, Lynch JP. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20: 623-651
• 341 Feinsilver SH, Fein AM, Niederman MS et al. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest 1990; 98: 1322-1326
• 342 van der Eerden MM, Vlaspolder F, de Graaff CS et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241-249
• 343 Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J 2001; 18: 196-208
• 344 Tomiyama N, Müller NL, Johkoh T et al. Acute parenchymal lung disease in immunocompetent patients: diagnostic accuracy of high-resolution CT. AJR Am J Roentgenol 2000; 174: 1745-1750
• 345 Pande A, Nasir S, Rueda AM et al. The incidence of necrotizing changes in adults with pneumococcal pneumonia. Clin Infect Dis 2012; 54: 10-16
• 346 Tkatch LS, Kusne S, Irish WD et al. Epidemiology of legionella pneumonia and factors associated with legionella-related mortality at a tertiary care center. Clin Infect Dis 1998; 27: 1479-1486
• 347 Ewig S, Schäfer H. Lungenabszesse neu betrachtet. Eine klinisch handlungsanleitende Klassifikation. Pneumologie 2001; 55: 195-201
• 348 Magalhães L, Valadares D, Oliveira JR et al. Lung abscesses: review of 60 cases. Rev Port Pneumol 2009; 15: 165-178
• 349 Leroy O, Vandenbussche C, Coffinier C et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med 1997; 156: 1922-1929
• 350 Nakagawa T, Sekizawa K, Arai H et al. High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 1997; 157: 321-324
• 351 Loeb M, McGeer A, McArthur M et al. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med 1999; 159: 2058-2064
• 352 Quagliarello V, Ginter S, Han L et al. Modifiable risk factors for nursing home-acquired pneumonia. Clin Infect Dis 2005; 40: 1-6
• 353 Almirall J, Bolíbar I, Serra-Prat M et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008; 31: 1274-1284
• 354 van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM et al. Risk factors for aspiration pneumonia in frail older people: a systematic literature review. J Am Med Dir Assoc 2011; 12: 344-354
• 355 Almirall J, Rofes L, Serra-Prat M et al. Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly. Eur Respir J 2013; 41: 923-928
• 356 Allewelt M, Schüler P, Bölcskei PL et al. Ampicillin + sulbactam vs clindamycin +/− cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect 2004; 10: 163-170
• 357 Ott SR, Allewelt M, Lorenz J et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008; 36: 23-30
• 358 Honda O, Tsubamoto M, Inoue A et al. Pulmonary cavitary nodules on computed tomography: differentiation of malignancy and benignancy. J Comput Assist Tomogr 2007; 31: 943-949
• 359 Li BG, Ma DQ, Xian ZY et al. The value of multislice spiral CT features of cavitary walls in differentiating between peripheral lung cancer cavities and single pulmonary tuberculous thick-walled cavities. Br J Radiol 2012; 85: 147-152
• 360 Görich J, Gamroth A, Beyer-Enke St et al. Computertomographische Differentialdiagnostik einschmelzender pulmonaler Raumforderungen. Fortschr Röntgenstr 1987; 147: 479-485
• 361 Park Y, Kim TS, Yi CA et al. Pulmonary cavitary mass containing a mural nodule: differential diagnosis between intracavitary aspergilloma and cavitating lung cancer on contrast-enhanced computed tomography. Clin Radiol 2007; 62: 227-232
• 362 He H, Stein MW, Zalta B et al. Pulmonary infarction: spectrum of findings on multidetector helical CT. J Thorac Imaging 2006; 21: 1-7
• 363 Khan MA, Dar AM, Kawoosa NU et al. Clinical profile and surgical outcome for pulmonary aspergilloma: nine year retrospective observational study in a tertiary care hospital. Int J Surg 2011; 9: 267-271
• 364 Lynch DA, Simone PM, Fox MA et al. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr 1995; 19: 353-360
• 365 Vourtsi A, Gouliamos A, Moulopoulos L et al. CT appearance of solitary and multiple cystic and cavitary lung lesions. Eur Radiol 2001; 11: 612-622
• 366 Gadkowski LB, Stout JE. Cavitary pulmonary disease. Clin Microbiol Rev 2008; 21: 305-333
• 367 Yang PC, Luh KT, Lee YC et al. Lung abscesses: US examination and US-guided transthoracic aspiration. Radiology 1991; 180: 171-175
• 368 Hammond JM, Potgieter PD, Hanslo D et al. The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. Chest 1995; 108: 937-941
• 369 Mansharamani N, Balachandran D, Delaney D et al. Lung abscess in adults: clinical comparison of immunocompromised to non-immunocompromised patients. Respir Med 2002; 96: 178-185
• 370 Wang JL, Chen KY, Fang CT et al. Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes. Clin Infect Dis 2005; 40: 915-922
• 371 Takayanagi N, Kagiyama N, Ishiguro T et al. Etiology and outcome of community-acquired lung abscess. Respiration 2010; 80: 98-105
• 372 Perlino CA. Metronidazole vs clindamycin treatment of anerobic pulmonary infection. Failure of metronidazole therapy. Arch Intern Med 1981; 141: 1424-1427
• 373 Levison ME, Mangura CT, Lorber B et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983; 98: 466-471
• 374 Gudiol F, Manresa F, Pallares R et al. Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990; 150: 2525-2529
• 375 Germaud P, Poirier J, Jacqueme P et al. Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess. Apropos of 57 cases. Rev Pneumol Clin 1993; 49: 137-141
• 376 Fernández-Sabé N, Carratalà J, Dorca J et al. Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections. Eur J Clin Microbiol Infect Dis 2003; 22: 185-187
• 377 Moreira Jda S, Camargo Jde J, Felicetti JC et al. Lung abscess: analysis of 252 consecutive cases diagnosed between 1968 and 2004. J Bras Pneumol 2006; 32: 136-143
• 378 Herth F, Ernst A, Becker HD. Endoscopic drainage of lung abscesses: technique and outcome. Chest 2005; 127: 1378-1381
• 379 Van Sonnenberg E, D'Agostino HB, Casola G et al. Lung abscess: CT-guided drainage. Radiology 1991; 178: 347-351
• 380 Klein JS, Schultz S, Heffner JE. Interventional radiology of the chest: image-guided percutaneous drainage of pleural effusions, lung abscess, and pneumothorax. AJR Am J Roentgenol 1995; 164: 581-588
• 381 Yunus M. CT guided transthoracic catheter drainage of intrapulmonary abscess. J Pak Med Assoc 2009; 59: 703-709
• 382 Kelogrigoris M, Tsagouli P, Stathopoulos K et al. CT-guided percutaneous drainage of lung abscesses: review of 40 cases. JBR-BTR 2011; 94: 191-195
• 383 Reimel BA, Krishnadasen B, Cuschieri J et al. Surgical management of acute necrotizing lung infections. Can Respir J 2006; 13: 369-373
• 384 Schweigert M, Dubecz A, Beron M et al. Surgical therapy for necrotizing pneumonia and lung gangrene. Thorac Cardiovasc Surg 2013; 61: 636-641
• 385 Heffner JE, McDonald J, Barbieri C et al. Management of parapneumonic effusions. An analysis of physician practice patterns. Arch Surg 1995; 130: 433-438
• 386 Light RW, Girard WM, Jenkinson SG et al. Parapneumonic effusions. Am J Med 1980; 69: 507-512
• 387 Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest 1978; 74: 170-173
• 388 Falguera M, Carratalà J, Bielsa S et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J 2011; 38: 1173-1179
• 389 Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997; 10: 2411-2418
• 390 Heffner JE, Brown LK, Barbieri C et al. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995; 151: 1700-1708
• 391 Chalmers JD, Singanayagam A, Murray MP et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009; 64: 592-597
• 392 Maskell NA, Maskell NA, Davies CW et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005; 352: 865-874
• 393 Light RW. A new classification of parapneumonic effusions and empyema. Chest 1995; 108: 299-301
• 394 Rahman NM, Mishra EK, Davies HE et al. Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose. Am J Respir Crit Care Med 2008; 178: 483-490
• 395 Bouros D, Schiza S, Tzanakis N et al. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med 1999; 159: 37-42
• 396 Diacon AH, Theron J, Schuurmans MM et al. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004; 170: 49-53
• 397 Thommi G, Shehan JC, Robison KL et al. A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respir Med 2012; 106: 716-723
• 398 Rahman NM, Maskell NA, West A et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365: 518-526
• 399 Janda S, Swiston J. Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta-analysis. Chest 2012; 142: 401-411
• 400 Gonzalez M, Ris H-B, Petrov D. Surgical management of pleural empyema. Eur Respir Monogr 2013; 61: 141-152
• 401 Taylor JK, Fleming GB, Singanayagam A et al. Risk factors for aspiration in community-acquired pneumonia: analysis of a hospitalized UK cohort. The American journal of medicine 2013; 126: 995-1001
• 402 Wei C, Cheng Z, Zhang L et al. Microbiology and prognostic factors of hospital- and community-acquired aspiration pneumonia in respiratory intensive care unit. Am J Infect Control 2013; 41: 880-884
• 403 Miyashita N, Kawai Y, Akaike H et al. Clinical features and the role of atypical pathogens in nursing and healthcare-associated pneumonia (NHCAP): differences between a teaching university hospital and a community hospital. Intern Med 2012; 51: 585-594
• 404 Giannella M, Pinilla B, Capdevila JA et al. Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. Clin Microbiol Infect 2012; 18: 786-794
• 405 Garcia-Vidal C, Carratalà J, Fernández-Sabé N et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect 2009; 15: 1033-1038
• 406 Lauterbach E, Voss F, Gerigk R et al. Bacteriology of aspiration pneumonia in patients with acute coma. Intern Emerg Med 2014; 9: 879-885
• 407 Marik PE. Pulmonary aspiration syndromes. Curr Opin Pulm Med 2011; 17: 148-154
• 408 Carratalà J, Rosón B, Fernández-Sevilla A et al. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med 1998; 158: 868-872
• 409 Tiep B, Carter R, Zachariah F et al. Oxygen for end-of-life lung cancer care: managing dyspnea and hypoxemia. Expert Rev Respir Med 2013; 7: 479-490
• 410 Truog RD, Campbell ML, Curtis JR et al. Recommendations for end-of-life care in the intensive care unit: a consensus statement by the American College [corrected] of Critical Care Medicine. Crit Care Med 2008; 36: 953-963
• 411 Kacmarek RM. Should noninvasive ventilation be used with the do-not-intubate patient?. Respir Care 2009; 54: 223-229
• 412 Azoulay E, Demoule A, Jaber S et al. Palliative noninvasive ventilation in patients with acute respiratory failure. Intensive Care Med 2011; 37: 1250-1257
• 413 Michiels B, Govaerts F, Remmen R et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011; 29: 9159-9170
• 414 Manzoli L, Ioannidis JP, Flacco ME et al. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother 2012; 8: 851-862
• 415 Osterholm MT, Kelley NS, Sommer A et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 36-44
• 416 Jefferson T, Di Pietrantonj C, Al-Ansary LA et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; 2: CD004876
• 417 Jefferson T, Di Pietrantonj C, Rivetti A et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7: CD001269
• 418 Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2010; 2: CD005187
• 419 Moberley S, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422
• 420 Maruyama T, Taguchi O, Niederman MS et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340: c1004
• 421 Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study. Hum Vaccin Immunother 2012; 8: 639-644
• 422 Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58: 909-917
• 423 Russell KL, Baker CI, Hansen C et al. Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial. Vaccine 2015; 33: 1182-1187
• 424 Bonten MJ, Huijts SM, Bolkenbaas M et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-1125
• 425 Richter SS, Diekema DJ, Heilmann KP et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 2014; 58: 6484-6489
• 426 Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2014. Epidemiologisches Bulletin 2014; 34: 305-340
• 427 Tomczyk S, Bennett NM, Stoecker C et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63: 822-825
• 428 Trosini-Desert V, Germaud P, Dautzenberg B. Tobacco smoke and risk of bacterial infection. Rev Mal Respir 2004; 21: 539-547
• 429 Almirall J, Bolíbar I, Balanzó X et al. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999; 13: 349-355
• 430 Cecere LM, Williams EC, Sun H et al. Smoking cessation and the risk of hospitalization for pneumonia. Respir Med 2012; 106: 1055-1062
• 431 Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165-1177
• 432 Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310-319
• 433 Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5: 337-344
• 434 Lambert AA, Lam JO, Paik JJ et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PloS one 2015; 10: e0128004
• 435 Eurich DT, Sadowski CA, Simpson SH et al. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med 2010; 123: 47-53
• 436 Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008; 31: 627-636
• 437 Dublin S, Walker RL, Jackson ML et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 792-802
• 438 Filion KB, Chateau D, Targownik LE et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63: 552-558
• 439 Pratt N, Roughead EE, Salter A et al. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol 2012; 12: 72
• 440 Dublin S, Walker RL, Jackson ML et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc 2011; 59: 1899-1907
• 441 Obiora E, Hubbard R, Sanders RD et al. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013; 68: 163-170
• 442 Eurich DT, Lee C, Marrie TJ et al. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis 2013; 57: 1138-1144
• 443 Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3: CD010115
• 444 DiSantostefano RL, Li H, Hinds D et al. Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis 2014; 9: 457-468
• 445 Suissa S, Patenaude V, Lapi F et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036
• 446 Mapel D, Schum M, Yood M et al. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 2010; 19: 109-117
• 447 Festic E, Bansal V, Gajic O et al. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 2014; 89: 154-162
• 448 Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719
• 449 McKeever T, Harrison TW, Hubbard R et al. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest 2013; 144: 1788-1794
• 450 OʼByrne PM, Pedersen S, Carlsson LG et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183: 589-595
• 451 Liu CL, Shau WY, Chang CH et al. Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. J Epidemiol 2013; 23: 344-350
• 452 Dublin S, Walker RL, Jackson ML et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. Pharmacoepidemiology and drug safety 2012; 21: 1173-1182
• 453 Myles PR, Hubbard RB, McKeever TM et al. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009; 18: 269-275
• 454 van de Garde EM, Souverein PC, Hak E et al. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens 2007; 25: 235-239
• 455 Shinohara Y, Origasa H. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. Adv Ther 2012; 29: 900-912
• 456 Ohkubo T, Chapman N, Neal B et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169: 1041-1045
• 457 Schlienger RG, Fedson DS, Jick SS et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27: 325-332
• 458 Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract 2011; 61: e742-748
• 459 Dublin S, Jackson ML, Nelson JC et al. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009; 338: b2137
• 460 Fleming DM, Verlander NQ, Elliot AJ et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005–2006. Epidemiol Infect 2010; 138: 1281-1288
• 461 Marrie TJ. Pneumonia in the long-term-care facility. Infect Control Hosp Epidemiol 2002; 23: 159-164
• 462 Baine WB, Yu W, Summe JP. Epidemiologic trends in the hospitalization of elderly Medicare patients for pneumonia, 1991-1998. Am J Public Health 2001; 91: 1121-1123
• 463 Jungheim M, Schwemmle C, Miller S et al. [Swallowing and dysphagia in the elderly]. HNO 2014; 62: 644-651
• 464 van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM et al. Meta-analysis of dysphagia and aspiration pneumonia in frail elders. J Dent Res 2011; 90: 1398-1404
• 465 Leslie P, Drinnan MJ, Ford GA et al. Swallow respiratory patterns and aging: presbyphagia or dysphagia?. J Gerontol A Biol Sci Med Sci 2005; 60: 391-395
• 466 Kim SY, Kim TU, Hyun JK et al. Differences in videofluoroscopic swallowing study (VFSS) findings according to the vascular territory involved in stroke. Dysphagia 2014; 29: 444-449
• 467 Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344: 665-671
• 468 Yoneyama T, Yoshida M, Ohrui T et al. Oral care reduces pneumonia in older patients in nursing homes. J Am Geriatr Soc 2002; 50: 430-433
• 469 van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM et al. Oral health care and aspiration pneumonia in frail older people: a systematic literature review. Gerodontology 2013; 30: 3-9
• 470 Sjögren P, Nilsson E, Forsell M et al. A systematic review of the preventive effect of oral hygiene on pneumonia and respiratory tract infection in elderly people in hospitals and nursing homes: effect estimates and methodological quality of randomized controlled trials. J Am Geriatr Soc 2008; 56: 2124-2130
• 471 Gomes GF, Pisani JC, Macedo ED et al. The nasogastric feeding tube as a risk factor for aspiration and aspiration pneumonia. Curr Opin Clin Nutr Metab Care 2003; 6: 327-333
• 472 DiBartolo MC. Careful hand feeding: a reasonable alternative to PEG tube placement in individuals with dementia. J Gerontol Nurs 2006; 32: 25-33
• 473 Cichero JA. Thickening agents used for dysphagia management: effect on bioavailability of water, medication and feelings of satiety. Nutr J 2013; 12: 54
• 474 Carnaby G, Hankey GJ, Pizzi J. Behavioural intervention for dysphagia in acute stroke: a randomised controlled trial. Lancet Neurol 2006; 5: 31-37
• 475 Teismann IK, Steinsträter O, Warnecke T et al. Tactile thermal oral stimulation increases the cortical representation of swallowing. BMC neuroscience 2009; 10: 71
• 476 Rofes L, Arreola V, López I et al. Effect of surface sensory and motor electrical stimulation on chronic poststroke oropharyngeal dysfunction. Neurogastroenterol Motil 2013; 25: 888-e701
• 477 Rhee WI, Won SJ, Ko SB. Diagnosis with manometry and treatment with repetitive transcranial magnetic stimulation in Dysphagia. Ann Rehabil Med 2013; 37: 907-912
• 478 Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 2003; 124: 328-336
• 479 Huang J, Cao Y, Liao C et al. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care 2010; 14: R194
• 480 Kobayashi H, Nakagawa T, Sekizawa K et al. Levodopa and swallowing reflex. Lancet 1996; 348: 1320-1321
• 481 Nakagawa T, Wada H, Sekizawa K et al. Amantadine and pneumonia. Lancet 1999; 353: 1157
• 482 Sato E, Ohrui T, Matsui T et al. Folate deficiency and risk of pneumonia in older people. J Am Geriatr Soc 2001; 49: 1739-1740
• 483 Kulnik ST, Birring SS, Moxham J et al. Does respiratory muscle training improve cough flow in acute stroke? Pilot randomized controlled trial. Stroke 2015; 46: 447-453
• 484 Torres A, Peetermans WE, Viegi G et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013; 68: 1057-1065
• 485 Marrie TJ, Lau CY, Wheeler SL et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-755
• 486 Hauck LD, Adler LM, Mulla ZD. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol 2004; 14: 669-675
• 487 Loeb M, Carusone SC, Goeree R et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA 2006; 295: 2503-2510
• 488 Metersky ML, Waterer G, Nsa W et al. Predictors of in-hospital vs postdischarge mortality in pneumonia. Chest 2012; 142: 476-481
• 489 Dharmarajan K, Hsieh AF, Lin Z et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013; 309: 355-363
• 490 Thommen D, Weissenberger N, Schuetz P et al. Head-to-head comparison of length of stay, patients outcome and satisfaction in Switzerland before and after SwissDRG-Implementation in 2012: an observational study in two tertiary university centers. Swiss Med Wkly 2014; 144: w13972
• 491 Zasowski E, Butterfield JM, McNutt LA et al. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. Antimicrob Agents Chemother 2014; 58: 3804-3813
• 492 Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-2084
• 493 Bordon J, Aliberti S, Duvvuri P et al. Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. Int J Infect Dis 2013; 17: e293-298
• 494 Frei CR, Attridge RT, Mortensen EM et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther 2010; 32: 293-299
• 495 McCabe C, Kirchner C, Zhang H et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009; 169: 1525-1531
• 496 Gleason PP, Meehan TP, Fine JM et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-2572
• 497 Guo Q, Li HY, Li YM et al. Compliance with severe sepsis bundles and its effect on patient outcomes of severe community-acquired pneumonia in a limited resources country. Arch Med Sci 2014; 10: 970-978
• 498 https://www.sqg.de/downloads/Bundesauswertungen/2013/bu_Gesamt_PNEU_2013.pdf